Selgantolimod Inhibitor

Selgantolimod is an effective and selective toll-like receptor 8 agonists for the treatment,of the hepatitis B virus and human immunodeficiency virus infection.

Jules Levin. Efficacy and Safety of Oral TLR8 Agonist Selgantolimod in Virally Suppressed Adult Patients With Chronic Hepatitis B: a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. 2019 Nov 8-12.
Jules Levin. Efficacy and Safety of Oral TLR8 Agonist Selgantolimod in Virally Suppressed Adult Patients With Chronic Hepatitis B: a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. 2019 Nov 8-12.
Benjamin Ryan. Selgantolimod Shows Promise as treatment, for Hepatitis B. November 18, 2019.
Benjamin Ryan. Selgantolimod Shows Promise as treatment, for Hepatitis B. November 18, 2019.
Romas Geleziunas, et al. Modulators of toll-like receptors for the treatment,of hiv. US20170071944A1.
Romas Geleziunas, et al. Modulators of toll-like receptors for the treatment,of hiv. US20170071944A1.

Small volumes of Selgantolimod, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5755522 is an inhibitor targeting Selgantolimod.